Acarbose

證據等級: L5

預測適應症: 9 個

Acarbose: Evaluation Report — Insufficient Data for Repurposing Assessment

One-Sentence Summary

Acarbose (DB00284) is a known antidiabetic agent whose original indications are not recorded in this Evidence Pack. The current TxGNN pipeline returned no repurposing predictions for this drug, and multiple blocking data gaps (MOA, regulatory records, safety data) prevent a complete evaluation at this stage.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack
Predicted New Indication	Not available
TxGNN Prediction Score	Not available
Evidence Level	L5 — Model prediction not generated; no supporting studies
Taiwan Market Status	未上市 (Not marketed)
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for Acarbose in this Evidence Pack. As a result, a mechanistic rationale connecting an original indication to a new predicted indication cannot be constructed at this time.

Currently, detailed mechanism of action data is not available in the evidence pack (recorded as a High-severity data gap, DG002). Without MOA information, any mechanistic bridging argument between Acarbose’s established therapeutic use and a candidate new indication would be speculative rather than evidence-based.

Additionally, the original indication fields are empty in this Evidence Pack. A complete evaluation requires at minimum: confirmed original indication, TxGNN score and predicted disease target, and MOA data. These prerequisites must be addressed before this section can be meaningfully completed.

Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication to search against).

Literature Evidence

Currently no related literature available (no predicted indication to search against).

Taiwan Market Information

No regulatory licenses found. Acarbose has zero recorded authorizations in the Taiwan FDA database as of the data cutoff (2026-04-19).

Safety Considerations

Please refer to the package insert for safety information.

All safety fields in this Evidence Pack are recorded as data gaps:

Key warnings: not retrieved

Contraindications: not retrieved

Drug–drug interactions: query returned no results (status: not_found)

The TFDA package insert should be consulted directly to obtain warnings and contraindications before any further evaluation step.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN repurposing predictions for Acarbose, and two unresolved data gaps (DG001 — Blocking; DG002 — High) prevent entry into even the first stage of safety pre-screening. Proceeding without these inputs would produce an unreliable assessment.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve Taiwan FDA package insert (仿單): download PDF from the TFDA website and extract warnings and contraindications to unlock S1 safety pre-screening.
[DG002 — High] Retrieve MOA data from DrugBank API (DB00284) to enable mechanistic relevance analysis.
Re-run TxGNN pipeline to generate predicted indications with scores; the current run returned an empty predicted_indications array — verify whether the drug was successfully mapped in the knowledge graph and whether the prediction step executed correctly.
Once predictions are available, collect clinical trial and literature evidence via ClinicalTrials.gov and PubMed for the top-ranked predicted indication.
Verify whether Acarbose has any active global approvals (e.g., US FDA, EMA) that were not captured in the Taiwan regulatory query, and cross-check for any relevant real-world indication expansions.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.